Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 797,900 shares, a growth of 1,280.4% from the January 31st total of 57,800 shares. Based on an average daily volume of 764,400 shares, the short-interest ratio is currently 1.0 days. Currently, 2.1% of the company’s stock are sold short.

Institutional Trading of Achilles Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BML Capital Management LLC grew its holdings in shares of Achilles Therapeutics by 555.8% in the third quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after acquiring an additional 3,474,828 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Achilles Therapeutics in the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new position in shares of Achilles Therapeutics in the fourth quarter valued at approximately $57,000. Two Sigma Investments LP grew its holdings in shares of Achilles Therapeutics by 190.1% in the fourth quarter. Two Sigma Investments LP now owns 61,637 shares of the company’s stock valued at $70,000 after acquiring an additional 40,388 shares in the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of Achilles Therapeutics by 52.7% in the fourth quarter. Two Sigma Advisers LP now owns 34,200 shares of the company’s stock valued at $39,000 after acquiring an additional 11,800 shares in the last quarter. 56.38% of the stock is owned by institutional investors.

Achilles Therapeutics Stock Performance

Shares of ACHL opened at $1.39 on Friday. The stock has a 50 day moving average price of $1.23 and a two-hundred day moving average price of $1.03. The firm has a market capitalization of $57.13 million, a P/E ratio of -0.84 and a beta of 1.32. Achilles Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.76.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.